Evidence map›Paper›PMID 42337333›Full record

ArticleEuropean journal of human genetics : EJHG2026

Hemizygous loss-of-function variants of EIF1AX are associated with a syndromic neurodevelopmental disorder.

Kazuyuki Komatsu, Atsushi Sugie, Yohei Nitta, Jiro Osaka, Ummul Halilunnisa Mansoor Hussain, Mitsuru Kubota, Nobuyuki Shimozawa, Melissa T Carter, Petra J G Zwijnenburg, Quinten Waisfisz and 4 more

Erratum issuedAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Beyond the sequence.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Kazuyuki KomatsuDepartment of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0001-9861-8412
Atsushi SugieBrain Research Institute, Niigata University, Niigata, Japan. sugie@kit.ac.jp.ORCID http://orcid.org/0000-0002-2090-8839
Yohei NittaBrain Research Institute, Niigata University, Niigata, Japan.ORCID http://orcid.org/0000-0002-0712-428X
Jiro OsakaBrain Research Institute, Niigata University, Niigata, Japan.
Ummul Halilunnisa Mansoor HussainDepartment of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Mitsuru KubotaDepartment of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5395-8226
Nobuyuki ShimozawaDivision of Genomics Research, Life Science Research Center, Gifu University, Gifu, Japan.
Melissa T CarterDepartment of Genetics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
Petra J G ZwijnenburgDepartment of Human Genetics, Emma Center for Personalized Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Quinten WaisfiszDepartment of Human Genetics, Emma Center for Personalized Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Felix BoschannInstitute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-9410-9290
Denise HornInstitute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Mitsuko NakashimaDepartment of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan. sb8901@cc.saga-u.ac.jp.
Hirotomo SaitsuDepartment of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0003-0723-0960

Funding

Genome Canada (Génome Canada) OGI-147Japan Agency for Medical Research and Development (AMED) JP23ek0109549Japan Agency for Medical Research and Development (AMED) JP23ek0109637Japan Agency for Medical Research and Development (AMED) JP23ek0109674MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03641MEXT | Japan Society for the Promotion of Science (JSPS) JP21H02837MEXT | Japan Society for the Promotion of Science (JSPS) JP21K15619MEXT | Japan Society for the Promotion of Science (JSPS) JP23H02875
6 · The paper itself

Abstract

Pathogenic variants of genes encoding initiation factors can cause neurological diseases, including neurodevelopmental disorders and brain abnormalities. The eukaryotic translation initiation factor 1 A, X-linked (EIF1AX) is a gene located at Xp22.12 that plays an important role in the regulation of translation initiation. Here, we identified de novo hemizygous EIF1AX variants in male individuals with neurodevelopmental disorders and explored their possible involvement in these neurological disorders. We performed trio-based exome or whole genome sequencing in four families. The pathogenicity of EIF1AX variants was evaluated using a molecular dynamic simulation and transgenic Drosophila models. We identified four de novo hemizygous EIF1AX variants in four male individuals with variable neurodevelopmental delay, dysmorphic features, behavioral problems, ophthalmological abnormalities, and structural abnormalities in the brain. One variant was predicted to cause a splicing alteration, and minigene analysis confirmed exon skipping leading to the generation of a premature termination codon. In transgenic Drosophila harboring wild-type (WT) EIF1AX or the three other EIF1AX missense variants, overexpression of WT and the p.(Asn17Asp) variant caused structural abnormalities in the compound eye, whereas the p.(Lys64Glu) and p.(Asp90Gly) variants significantly reduced these eye abnormalities. In addition, WT overexpression resulted in significant axonal toxicity in the Drosophila optic nerve, causing a significant reduction in the number of axons, whereas all mutants showed only a mild reduction in axonal number. Our findings indicated that all variants resulted in different degrees of EIF1AX loss-of-function. Overall, EIF1AX is a novel gene for which loss-of-function variants appear to produce syndromic neurodevelopmental disorders in males.

Indexed as

Eukaryotic Initiation Factor-1Loss of Function MutationNeurodevelopmental DisordersAnimalsAnimals, Genetically ModifiedDrosophilaHemizygoteHumansMalePedigreeEukaryotic Initiation Factor-1eukaryotic peptide initiation factor-1A

Identifiers

PMID42337333
PMCPMC13424086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.